ADHD Therapeutics Market Size

Global ADHD Therapeutics Market Overview

The adhd therapeutics market is anticipated to reach USD 19.8 Billion by 2032 at 7.9% CAGR during the forecast period 2023-2032. According to the latest research report, it is anticipated that the ADHD Therapeutics Market would develop at a substantial rate throughout the projected period. Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) have persistent patterns of inattention and hyperactivity-impulsivity that interfere with their ability to function or grow normally.

Aspects such as the growing incidence of attention deficit hyperactivity disorder (ADHD), the increasing usage of chemical additives in children's food, and more awareness about ADHD are projected to drive the market's development. Comorbid disorders in children contribute to attention deficit hyperactivity disorder (ADHD) underdiagnosis. During the projected period, this factor will have a negative impact on market growth. Furthermore, the restricted accessibility of non-stimulant medications is projected to have a negative impact on the industry.

This report contains all the information on the global ADHD Therapeutics Market analysis and its strengths. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the ADHD Therapeutics Market forecast for 2030 is also included in the report.

During the early part of 2023, SpecGx L.L.C., a global specialty pharmaceuticals firm of Mallinckrodt plc (OTCMKTS: MNKTQ), got an Abbreviated New Drug Application approved by their Specialty Generics department for Lisdexamfetamine Dimesylate Capsules 10mg, 20mg, 30mg, 40mg, 50mg, 60mg and 70mg in August the same year. The F.D.A. said that its product is as good as Takeda Pharmaceuticals U.S.A., Inc.’s Vyvanse® Capsules in all seven strengths approved for the R.L.D. This is one of these drugs scarcity according to F.D.A. while it is used for Attention-Deficit/Hyperactivity Disorder (ADHD), which is a controlled substance under Schedule II according to federal law. For Takeda’s fiscal year ending March 31st, global sales of Lisdexamfetamine Dimesylate were greater than $3.0 billion.

Tris Pharma Inc., a company that focuses on attention deficit hyperactivity disorder (ADHD), pain management, addiction treatment, and neurological disorders at commercial-stage biopharmaceutical, filed its license agreement with Braingaze Ltd in April 2024. Since then, Tris Digital Health has manufactured digital diagnostic and therapeutic devices for neurological health conditions. In addition to Canada, it was granted exclusive rights to develop and sell Braingaze’s digital ADHD diagnostic platform in the U.S. alone by Tris. Braingaze is developing technology-driven diagnostic and treatment solutions for cognitive disorders.

Following positive top-line data released in May, Akili Interactive plans to release its video game treatment for attention deficit hyperactivity disorder to adults who want to use it. Akili’s Food and Drug Administration-cleared video game for children has a version called EndeavorOTC for adults that is now available on the Apple App Store without a doctor’s consultation or prescription requirements. The app will be submitted to the F.D.A. later, when it was launched under an April 2020 F.D.A. enforcement policy issued in response to the COVID-19 pandemic. Thus, companies were allowed by this policy to launch digital treatments for certain psychiatric illnesses without seeking agency clearance.

Covid 19 Analysis

With the COVID-19 outbreak and physical distancing tactics, people with hyperactivity disorder (ADHD) face an incredibly challenging moment. Individuals with ADHD may have an increase in behavioural issues as a consequence of these interventions. As a result of this, the ADHD market value, medications is expected to rise significantly.

As a consequence of panic purchases by customers, crucial drugs have run out of supply, necessitating the deployment of a fresh batch by players. ADHD medications are no exception.

The expansion of the market is anticipated to be fueled by factors such as the rising prevalence of attention deficit hyperactivity disorder (ADHD), the rising prevalence of chemical additives in children's food, and greater awareness of ADHD. Children with ADHD are underdiagnosed in part because of the prevalence of co-occurring illnesses. This aspect will restrain market expansion during the forecast time frame. A further detrimental influence on the market is anticipated from the limited availability of non-stimulant drugs.

Extensive studies evaluating the safety and efficacy of drugs for people with attention deficit hyperactivity disorder are expected to fuel market expansion in the near future. When these research yield positive results, it opens up new avenues for business. Opportunities for growth may arise if market leaders increase their product promotion activities.

As more people (including patients, doctors, and other healthcare professionals) learn about attention deficit hyperactivity disorder, the market for therapeutics to treat it is expected to expand. These possibilities are expected to increase the demand for ADHD treatment solutions. The advertising and partnership agreements for the product will have a greater impact because of the increased size of the sales force.

May 2023: Researchers found that Akili's EndeavorRx, a video game-based treatment for ADHD, improved adults' sustained and selective attention at a rate nearly seven times that of the original, younger test group, according to the study's primary outcomes, which were published in May 2023. The number of adults diagnosed with attention deficit hyperactivity disorder (ADHD) has been rising in recent years, and officials have speculated that the game-based treatment could fill a void in the market for non-drug ADHD remedies.

ADHD Therapeutics Market Trends  

Drivers

As more people become aware of attention deficit hyperactivity disorder (ADHD) among patients, doctors, and other medical practitioners, the need for effective treatment is expected to rise, resulting in ADHD Therapeutics market growth.

Opportunities

Due to the existence of solid wholesalers and distribution channels in Germany, the market of ADHD therapeutics in Europe is expected to be dominated by the country. Opportunities for ADHD treatment systems in such areas are expected to expand the market. A larger sales team will also increase the product's marketing and partnership agreements' reach throughout these two areas.

Restraints

Adverse reactions and contraindications to ADHD medications are restricting the number of scripts that may be issued, which is predicted to have an impact on income.

Challenges

Among the most significant challenges facing the worldwide ADHD therapeutics market outlook are the high cost of ADHD drugs, inappropriate funding procedures, and side effects associated with ADHD medications such as sleeplessness, anorexia, nausea, migraines, and mood abnormalities.

Cumulative Growth Analysis

According to data published by the Centers for Disease Control and Prevention (CDC), roughly 6.1 million people, which is 9.4 per cent in the United States, were identified with attention deficit hyperactivity disorder ADHD in 2016. This contains 388,000 kids aged 2–5 years, 4 million kids aged 6–11 years, and 3 million kids aged 12–17 years. In addition, males are more likely than females to be involved in Developing, according to the American Academy of Pediatrics.

The frequency of attention-deficit hyperactivity disorder (ADHD) is increasing at an astonishing rate, which is projected to drive sales increase in the worldwide market of ADHD therapeutics, which currently lacks a therapy for the illness in question.

ADHD Therapeutics Market Segment Insights

According to the reports, The market of ADHD therapeutics has been divided based on the Drug type, age range, end-user, and geographic area in which it operates. 

ADHD therapeutics Drug Insights

by drug type The market of ADHD therapeutics has been segmented into two groups stimulants and non-stimulants. The stimulants sector is further subdivided into the following categories: amphetamine, dexmethylphenidate, methylphenidate, lisdexamfetamine, dextroamphetamine, and other stimulants. Because of physicians' strong preference for medicine, the lisdexamfetamine sub-segment is likely to be the most significant section in the market. Non-stimulants are further subdivided into atomoxetine, guanfacine, bupropion, and clonidine, which are all antidepressants.

ADHD therapeutics Age Group Insights

by age group the market of ADHD therapeutics market has been segmented into paediatrics, adolescents and adults.

ADHD therapeutics End-User Insights

Depending on the end-user, the market for ADHD therapies has been categorized into hospitals & clinics, specialist clinics, and other organizations.

June 2023: Cingulate's CTx-1301 (dexmethylphenidate) trial to treat adult attention-deficit/hyperactivity disorder (ADHD) was completed in June 2023. The start and duration of CTx-1301 were assessed in an adult laboratory classroom (ALC) setting as part of a parallel effectiveness and safety, placebo-controlled, double-blind, dose-optimized, single-centre, randomized investigation. In addition, a dose-optimization onset and duration trial in pediatric patients, as well as a Phase III fixed-dose research in children and adolescents, are scheduled to begin in the third quarter of 2023.

June 2023: Cingulate's CTx-1301 (dexmethylphenidate) trial to treat adult attention-deficit/hyperactivity disorder (ADHD) was completed in June 2023. The start and duration of CTx-1301 were assessed in an adult laboratory classroom (ALC) setting as part of a parallel effectiveness and safety, placebo-controlled, double-blind, dose-optimized, single-centre, randomized investigation. In addition, a dose-optimization onset and duration trial in pediatric patients, as well as a Phase III fixed-dose research in children and adolescents, are scheduled to begin in the third quarter of 2023.

ADHD therapeutics Regional Insights

According to the reports, The ADHD Therapeutics Market is bifurcated into the Americas, Europe, Asia-Pacific, and the Middle East & Africa in terms of geographic location. It is expected that the Americas would lead the market for ADHD treatments due to the region's well-developed healthcare system, increased incidence of ADHD and early authorization of medicines. A maximum of 6.1 million American children was diagnosed with ADHD between 2012 and 2016.

As a result of government assistance and improved healthcare r & d, Europe is believed to maintain second place in the ADHD therapeutics market share. This region's ADHD treatment market includes all of Asia-countries Pacific's including but not limited to: India, China, Australia, Japan, South Korea, and the rest. As the incidence of ADHD rises and healthcare costs rise, Asia-Pacific is predicted to be a high-speed area in the global ADHD market. Children and teenagers in China have an ADHD prevalence of 6.26 per cent, according to a report released by the National Center for Biotechnology Information in January 2017.

The Middle East and Africa are predicted to have the smallest market share during the projected period. The medical system in this area is projected to fuel the market's development.

Competitive landscape

Manufacturers are targeting both youngsters with ADHD and adults with the disorder. To make them more appealing to children, certain medications are flavoured to make them more palatable, while for grownups, the goal is to provide a long-lasting impact so that they don't have to take as many tablets each day.

Major Key Players

• Advanz Pharmaceutical (Canada)


• Eli Lilly and Company (US)


• Highland Therapeutics Inc. (Canada)


• Janssen Pharmaceuticals, Inc. (Belgium)


• NEOS Therapeutics, Inc. (US)


• Pfizer Inc. (US)


• Novartis AG (Switzerland)


• Noven Pharmaceuticals, Inc. (US)


• Shire (US)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Impax Laboratories, LLC (US)


• GlaxoSmithKline plc (UK)


• Purdue Pharma L.P. (US)

Report Overview

The following report comprises of –

• Market overview 


• Covid 19 Analysis


• Market Dynamic


• Drivers


• Opportunities


• Restraints 


• Challenges


• Cumulative Growth Analysis


• Value Chain Analysis


• Segmentation Overview 


• By Application 


• By End-Users


• Regional Analysis


• Competitive landscape

Recent Developments

• Tris Pharma Inc. completed the acquisition of NextWave Pharmaceuticals in September 2018, therefore expanding its ADHD product range.

ADHD therapeutics Market Segmentation

ADHD Therapeutics Drug Type Outlook

• Stimulants
  
  
  
  • Amphetamine
  
  
  • Methylphenidate
  
  
  • Dextroamphetamine
  
  
  • Dexmethylphenidate
  
  
  • Lisdexamfetamine
  
  
  • Other
  
  
  
  


• Non-StimulantsAtomoxetine
  
  
  
  • Bupropion
  
  
  • Guanfacine
  
  
  • Clonidine
  
  
  
  

ADHD Therapeutics Age Group Outlook

• Pediatric and Adolescents


• Adults

ADHD Therapeutics End User Outlook

• Specialty Clinics


• Hospital Pharmacies


• Retail Pharmacies


• Others

ADHD Therapeutics Region Outlook

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    • Latin America
    
    
    
    
  
  
  
  


• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • UK
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa